Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-31 2024-12-31 2024-01-01 true true 1 The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 1 R&D false 04988521 2024-01-01 2024-12-31 04988521 2023-01-01 2023-12-31 04988521 2024-12-31 04988521 2023-12-31 04988521 c:Director1 2024-01-01 2024-12-31 04988521 d:CurrentFinancialInstruments 2024-12-31 04988521 d:CurrentFinancialInstruments 2023-12-31 04988521 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 04988521 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 04988521 d:ShareCapital 2024-12-31 04988521 d:ShareCapital 2023-12-31 04988521 d:RetainedEarningsAccumulatedLosses 2024-12-31 04988521 d:RetainedEarningsAccumulatedLosses 2023-12-31 04988521 c:OrdinaryShareClass1 2024-01-01 2024-12-31 04988521 c:OrdinaryShareClass1 2024-12-31 04988521 c:OrdinaryShareClass1 2023-12-31 04988521 c:FRS102 2024-01-01 2024-12-31 04988521 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 04988521 c:FullAccounts 2024-01-01 2024-12-31 04988521 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 04988521 e:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 04988521 MOLECULAR SYNTHETICS LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 DECEMBER 2024
MOLECULAR SYNTHETICS LIMITED REGISTERED NUMBER: 04988521 BALANCE SHEET AS AT 31 DECEMBER 2024
|  | 2024 |  | 2023
Note |  | £ |  | £
CURRENT ASSETS |  |  |  |  |
Debtors: amounts falling due within one year | 4 | 100 |  | 100 |
Creditors: amounts falling due within one year | 5 | (105,485) |  | (103,235) |
NET CURRENT LIABILITIES |  |  | (105,385) |  | (103,135)
NET LIABILITIES |  |  | (105,385) |  | (103,135)
CAPITAL AND RESERVES |  |  |  |  |
Called up share capital | 6 |  | 1,000 |  | 1,000
Profit and loss account |  |  | (106,385) |  | (104,135)
|  |  | (105,385) |  | (103,135)
The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
Dr M Bacon
Director
Date: 28 August 2025
The notes on pages 2 to 3 form part of these financial statements. Page 1
MOLECULAR SYNTHETICS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
1. | GENERAL INFORMATION
Molecular Synthetics Limited is a private company limited by shares and incorporated in England and Wales. The address of the registered office is Salisbury House, Station Road, Cambridge, CB1 2LA. The company has no permanent trading premises. The Company's functional and presentational currency is GBP and the figures are rounded to the nearest pound. 2.ACCOUNTING POLICIES
| 2.1 | BASIS OF PREPARATION OF FINANCIAL STATEMENTS
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | GOING CONCERN
In common with other development stage companies, the company has incurred a loss for the year and has net liabilities at the year end. The company has received assurances from the directors that they will continue to provide ongoing financial support to the company, and consequently the accounts are prepared on the going concern basis.
| 2.3 | DEBTORS
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.4 | CREDITORS
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | EMPLOYEES
| The Company has no employees other than the directors, who did not receive any remuneration (2023 - £NIL).
Page 2
MOLECULAR SYNTHETICS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
4. | DEBTORS
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Called up share capital not paid | 100 | 100
|  | 100 | 100
5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade creditors | 3,143 | 3,143
| Other creditors | 100,872 | 98,682
| Accruals and deferred income | 1,470 | 1,410
|  | 105,485 | 103,235
6. | SHARE CAPITAL
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
|  | ALLOTED, CALLED UP AND FULLY PAID |  |
|  | 900 (2023 - 900) Ordinary shares of £1 each shares of £1.00 each | 900 | 900
|  | ALLOTTED CALLED UP AND PARTLY PAID |  |
|  | 100 (2023 - 100) Ordinary shares of £1 each shares of £1.00 each | 100 | 100
Page 3